Premium
Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle‐aged and older subjects: results from a 5‐year follow‐up
Author(s) -
Dörr Marcus,
Ittermann Till,
Aumann Nicole,
Obst Anne,
Reffelmann Thorsten,
Nauck Matthias,
Wallaschofski Henri,
Felix Stephan B.,
Völzke Henry
Publication year - 2010
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2010.03882.x
Subject(s) - subclinical infection , medicine , left ventricular hypertrophy , cardiology , muscle hypertrophy , endocrinology , blood pressure
Summary Background Decreased serum TSH levels are associated with increased cardiovascular mortality in elderly, and subclinical hyperthyroidism (SCH) was associated with left ventricular hypertrophy (LVH) as a predictor of cardiovascular mortality in some cross‐sectional and case‐control studies. The aim was to assess whether SCH independently impacts development of LVH over time. Methods Of 3300 participants of the population‐based Study of Health in Pomerania those with overt hyperthyroidism, hypothyroidism, possible thyroid disease or missing echocardiographic baseline data or follow‐up were excluded, resulting in a study population of 1112 individuals (556 women) aged 45–81 years. Echocardiographic left ventricular mass divided by height 2·7 (LVMI ht ), and LVH ht (LVMI ht >44 g/m 2·7 in women and >48 g/m 2·7 in men) was measured at baseline and after 5‐year follow‐up (median 5·00; range 4·92; 5·08). Comparison of subjects with ( n = 107) and without ( n = 1005) SCH were made by linear and logistic regression models adjusted for age, gender, smoking status, hypertension, and waist circumference. Results At follow‐up, LVMI ht did not differ between subjects with and without SCH (50·2 g/m 2·7 , interquartile range (IQR) 41·2; 59·5 vs 47·8 g/m 2·7 , IQR 39·3; 56·9; P = 0·29). LVH ht was present in 66 (61·7%) subjects with and 543 (54·0%) persons without SCH ( P = 0·13). Analyses revealed no association between SCH and progression of LVMI ht (β = −0·18; 95%‐confidence interval (CI) −2·34; −1·99; P = 0·873), and development of LVH ht (relative risk 0·86, 95%‐CI 0·60; 1·26; P = 0·462), respectively. Conclusions In this population‐based sample, SCH had no impact on progression of LVMI and development of LVH during 5‐year follow‐up in subjects aged 45 years or older.